SCIENCE IN THE NEWS DAILY
Trials Overlook Cancer Spread
from the Scientist (Registration Required)
When people die from breast cancer, it is mostly because their original tumours have metastasized to other organs. However, clinical trials for cancer drugs are focused on shrinking existing tumors, not preventing cancer spread. According to Patricia Steeg from the National Cancer Institute, this emphasis is stifling the discovery of chemicals that could prevent metastasis--costing money and patient lives.
In a comment piece, published in Nature, Steeg calls on the US Food and Drug Administration (FDA) to usher in a new type of randomized clinical trial that will demonstrate if drugs could stop breast cancer from spreading.
Animal studies have identified several compounds could potentially prevent metastasis, but these chemicals often do not kill cancer cells or tumors that have already spread. When they make it to phase II clinical trials, which are designed to test their effectiveness, they fail to shrink established tumors and are no longer pursued as potential cancer treatments. As Steeg wrote in her piece, "the drug company loses the money invested in development; the scientists who worked on these compounds lose a potentially valid clinical lead compound; and the patients continue to lose their lives."
Connect With Us:
PODCAST & VIDEO: 3D Printing Replacement Body Parts
Regenerative medicine, a fledgling field with the aim of regrowing parts from a person’s own cells, is being amplified with 3D-printing technology, which can now use organic materials to create scaffolds that cells need to grow into their final forms. Richard Wysk, a professor of industrial and systems engineering at North Carolina State University, discusses the latest successes with this research, and the timeline for creating more complicated structures.
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.